Harrow closes TYRVAYA nasal spray acquisition from Viatris for USD 30 million upfront

Bitget2026/10/05 11:06

Harrow closed its acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris, gaining worldwide rights except Japan. Viatris retained Japan commercialization rights, agreeing to pay Harrow royalties on any future net sales there. Deal terms include USD 30 million cash paid at closing, with up to USD 70 million tied to net-sales milestones. Harrow expects TYRVAYA revenue to exceed USD 30 million in 2027 as it integrates the brand into its ocular surface franchise. Roughly 40 Viatris personnel are expected to join in Q4 2026 to expand Harrow’s dry-eye commercial team. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9839258) on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Michael Saylor releases bitcoin Tracker information again, possibly hinting at increasing BTC holdings

BlockBeats•2026/10/11 12:13

Crypto Pundit Says If You Are Holding XLM, Read This

TimesTabloid•2026/10/11 12:00

International gold prices are approaching the $4,200 mark, and Wall Street is bullish on next week's market.

新浪财经•2026/10/11 11:05

Only 1.45 Billion Shiba Inu (SHIB) Burned in 24 Hours Hints at Reversal

UToday•2026/10/11 10:27